Free Trial

Biogen (BIIB) Financials

Biogen logo
$127.53 -0.86 (-0.67%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$127.95 +0.42 (+0.33%)
As of 05/28/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Biogen

Annual Income Statements for Biogen

This table shows Biogen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders
1,632 1,161 3,047 1,556 4,001 5,889 4,431 2,539 3,703 3,547
Consolidated Net Income / (Loss)
1,632 1,162 2,962 1,728 4,061 5,889 4,474 2,670 3,696 3,593
Net Income / (Loss) Continuing Operations
1,632 1,162 2,962 1,728 4,061 5,889 4,474 2,670 3,696 3,593
Total Pre-Tax Income
1,906 1,297 3,592 1,745 5,048 7,126 5,900 5,129 4,933 4,767
Total Operating Income
2,250 1,612 3,484 1,745 4,550 7,043 5,889 5,346 5,152 4,891
Total Gross Profit
7,366 7,302 7,895 8,872 11,639 12,423 11,637 10,644 9,970 9,523
Total Revenue
9,676 9,836 10,173 10,982 13,445 14,378 13,453 12,274 11,449 10,764
Operating Revenue
9,676 9,836 10,173 10,982 13,445 14,378 13,453 12,274 11,449 10,528
Total Cost of Revenue
2,310 2,533 2,278 2,110 1,805 1,955 1,816 1,630 1,479 1,240
Operating Cost of Revenue
2,310 2,533 2,278 2,110 1,805 1,955 1,816 1,630 1,479 1,240
Total Operating Expenses
5,116 5,690 4,412 7,127 7,089 5,380 5,748 5,298 4,818 4,632
Selling, General & Admin Expense
2,404 2,550 2,404 2,674 2,505 2,375 2,106 1,934 1,947 2,113
Research & Development Expense
2,042 2,462 2,231 2,519 4,066 2,281 2,710 2,374 1,973 2,013
Amortization Expense
447 241 366 881 465 490 747 815 386 383
Other Operating Expenses / (Income)
254 219 -7.40 1,103 233 242 185 112 10 0.00
Restructuring Charge
30 219 131 0.00 0.00 1.50 12 0.90 33 93
Other Special Charges / (Income)
-61 0.00 -713 -51 -179 -8.40 -12 63 470 31
Total Other Income / (Expense), net
-344 -316 108 0.00 497 83 11 -217 -219 -124
Other Income / (Expense), net
-344 -316 108 - 497 83 11 -217 -219 -124
Income Tax Expense
274 135 633 53 992 1,158 1,426 2,459 1,237 1,162
Other Gains / (Losses), net
0.00 0.00 2.60 35 5.30 -79 0.00 0.00 0.00 -13
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 0.40 -85 172 60 0.00 43 131 -7.10 46
Basic Earnings per Share
$11.21 $8.02 $20.96 $10.44 $24.86 $31.47 $21.63 $11.94 $16.96 $15.38
Weighted Average Basic Shares Outstanding
145.60M 144.70M 145.30M 149.10M 160.90M 187.10M 204.90M 212.60M 218.40M 230.70M
Diluted Earnings per Share
$11.18 $7.97 $20.87 $10.40 $24.80 $31.42 $21.58 $11.92 $16.93 $15.34
Weighted Average Diluted Shares Outstanding
145.90M 145.60M 146M 149.60M 161.30M 187.40M 205.30M 213M 218.80M 231.20M
Weighted Average Basic & Diluted Shares Outstanding
146.37M 145.36M 144.49M 146.96M 152.34M 174.06M 204.80M 212.70M 218.30M 230.60M

Quarterly Income Statements for Biogen

This table shows Biogen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
241 267 389 584 393 250 -68 592 388 550 1,135
Consolidated Net Income / (Loss)
241 267 389 584 393 249 -68 593 388 550 1,135
Net Income / (Loss) Continuing Operations
241 267 389 584 393 249 -68 593 388 550 1,135
Total Pre-Tax Income
311 292 451 699 465 292 -141 708 438 604 1,371
Total Operating Income
311 635 451 699 465 607 -141 708 438 496 1,371
Total Gross Profit
1,802 1,871 1,827 1,919 1,748 1,768 1,871 1,863 1,800 1,973 2,039
Total Revenue
2,431 2,455 2,466 2,465 2,291 2,386 2,530 2,456 2,463 2,544 2,509
Operating Revenue
2,431 - - - - - - - - - -
Total Cost of Revenue
629 584 639 546 542 618 660 593 663 571 470
Operating Cost of Revenue
629 584 639 546 542 618 660 593 663 571 470
Total Operating Expenses
1,491 1,236 1,376 1,220 1,284 1,161 2,012 1,155 1,362 1,478 668
Selling, General & Admin Expense
573 680 588 554 582 609 788 548 605 633 563
Research & Development Expense
635 532 543 514 453 571 736 584 571 602 549
Amortization Expense
112 151 130 87 78 77 61 53 50 175 57
Other Operating Expenses / (Income)
127 -137 84 148 159 -194 351 -64 127 257 -11
Restructuring Charge
35 5.30 6.80 6.60 12 99 76 34 9.60 7.00 15
Other Special Charges / (Income)
9.60 - 24 -89 - - 0.00 0.00 - -195 -506
Total Other Income / (Expense), net
0.00 -344 0.00 0.00 0.00 -316 0.00 0.00 0.00 108 0.00
Income Tax Expense
71 25 63 115 71 43 -73 115 51 54 236
Basic Earnings per Share
$1.65 $1.82 $2.67 $4.01 $2.71 $1.71 ($0.47) $4.09 $2.69 $3.79 $7.86
Weighted Average Basic Shares Outstanding
146.10M 145.60M 145.70M 145.60M 145.20M 144.70M 144.80M 144.70M 144.40M 145.30M 144.40M
Diluted Earnings per Share
$1.64 $1.82 $2.66 $4.00 $2.70 $1.70 ($0.47) $4.07 $2.67 $3.73 $7.84
Weighted Average Diluted Shares Outstanding
146.60M 145.90M 146.10M 145.90M 145.90M 145.60M 144.80M 145.50M 145.20M 146M 144.80M
Weighted Average Basic & Diluted Shares Outstanding
146.53M 146.37M 145.72M 145.66M 145.60M 145.36M 144.90M 144.82M 144.74M 144.49M 144.00M

Annual Cash Flow Statements for Biogen

This table details how cash moves in and out of Biogen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents
1,393 -2,405 1,214 990 -1,652 1,689 -331 -792 1,050 149
Net Cash From Operating Activities
2,876 1,547 1,384 3,640 4,230 7,079 6,188 4,551 4,587 3,919
Net Cash From Continuing Operating Activities
2,876 1,547 1,384 3,640 4,230 7,026 6,188 4,551 4,587 3,919
Net Income / (Loss) Continuing Operations
1,632 1,162 2,962 1,728 4,061 5,889 4,474 2,670 3,696 3,593
Consolidated Net Income / (Loss)
1,632 1,162 2,962 1,728 4,061 5,889 4,474 2,670 3,696 3,593
Depreciation Expense
673 495 518 488 457 465 651 1,081 683 600
Amortization Expense
230 32 0.00 0.00 - - - - - -
Non-Cash Adjustments To Reconcile Net Income
653 814 -1,037 1,997 -250 407 555 473 259 322
Changes in Operating Assets and Liabilities, net
-313 -955 -1,059 -572 -38 266 509 327 -50 -596
Net Cash From Investing Activities
-799 -4,101 1,577 -564 -609 471 -2,046 -2,963 -2,485 -4,554
Net Cash From Continuing Investing Activities
-799 -4,101 1,577 -564 -609 471 -2,046 -2,963 -2,485 -4,554
Purchase of Property, Plant & Equipment
-154 -277 -240 -258 -425 -815 -2,271 -2,067 -1,816 -1,493
Acquisitions
-1,281 -6,961 -2.90 -37 -127 -899 -792 -1,095 -112 -214
Purchase of Investments
0.00 -5,141 -3,449 -3,809 -7,404 -5,253 -8,158 -5,355 -7,913 -6,865
Sale of Property, Plant & Equipment
89 0.00 0.00 28 0.00 924 0.00 0.00 - -
Divestitures
552 908 1,573 94 75 479 0.00 - - -
Sale and/or Maturity of Investments
0.00 7,381 3,671 3,405 7,299 6,007 9,174 5,566 7,379 4,063
Other Investing Activities, net
-4.70 -11 24 13 -27 27 0.40 -11 -23 -45
Net Cash From Financing Activities
-684 149 -1,747 -2,086 -5,273 -5,860 -4,472 -2,380 -1,053 783
Net Cash From Continuing Financing Activities
-684 149 -1,747 -2,086 -5,273 -5,860 -4,472 -2,380 -1,053 783
Repayment of Debt
-652 -816 -1,008 -191 -1,485 0.00 -25 -575 -2.70 -7.30
Repurchase of Common Equity
0.00 0.00 -750 -1,800 -6,679 -5,868 -4,353 -1,365 -1,000 -5,000
Payment of Dividends
0.00 12 12 -94 -71 4.30 -36 -437 0.00 -56
Issuance of Debt
0.00 997 0.00 0.00 2,967 3.60 0.00 - -2.80 5,931
Other Financing Activities, net
-31 -44 -1.90 -0.70 -4.60 0.00 -58 -3.00 -47 -84

Quarterly Cash Flow Statements for Biogen

This table details how cash moves in and out of Biogen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
189 750 -252 847 48 -1,286 -301 -276 -541 382 376
Net Cash From Operating Activities
259 761 936 626 553 13 592 487 455 -175 661
Net Cash From Continuing Operating Activities
259 761 936 626 553 13 592 487 455 -189 675
Net Income / (Loss) Continuing Operations
241 267 389 584 393 249 -68 593 388 550 1,135
Consolidated Net Income / (Loss)
241 267 389 584 393 249 -68 593 388 550 1,135
Depreciation Expense
183 184 183 159 148 140 125 117 112 120 121
Amortization Expense
51 45 51 90 44 32 - - 0.00 - -
Non-Cash Adjustments To Reconcile Net Income
136 319 108 69 157 168 428 14 204 298 -626
Changes in Operating Assets and Liabilities, net
-352 -54 205 -276 -189 -576 108 -237 -249 -1,156 45
Net Cash From Investing Activities
-47 -19 -1,181 467 -66 -652 -1,742 -754 -953 -141 1,672
Net Cash From Continuing Investing Activities
-47 -19 -1,181 467 -66 -652 -1,742 -754 -953 442 1,090
Purchase of Property, Plant & Equipment
-37 -39 -35 -34 -46 -65 -74 -71 -67 -86 -59
Acquisitions
-10 -1,102 -95 -9.10 -75 -6,926 -13 -16 -5.00 -1.00 -
Sale and/or Maturity of Investments
0.00 -97 39 1.90 56 -106 5,702 1,345 441 566 1,643
Other Investing Activities, net
-0.20 -0.30 -1.10 -2.60 -0.70 -10 -0.20 -0.40 -0.70 23 -0.20
Net Cash From Financing Activities
-23 7.90 -6.60 -245 -440 -646 849 -9.80 -43 -7.40 -1,252
Net Cash From Continuing Financing Activities
-23 7.90 -6.60 -245 -440 -646 849 -9.80 -43 -7.40 -1,252
Repayment of Debt
1.30 4.40 -13 -251 -393 -658 -158 -17 17 -12 -
Other Financing Activities, net
-24 3.50 6.00 6.10 -47 3.70 6.60 5.50 -60 3.90 5.70

Annual Balance Sheets for Biogen

This table presents Biogen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets
28,049 26,845 24,554 23,877 24,619 27,234 25,289 23,653 22,877 19,505
Total Current Assets
7,457 6,859 9,791 7,857 6,887 8,382 7,641 7,873 8,732 6,700
Cash & Equivalents
2,375 1,050 3,419 2,261 1,331 2,914 1,225 1,574 2,327 1,308
Accounts Receivable
1,405 1,664 1,705 1,549 1,914 1,881 1,959 1,787 1,442 1,227
Inventories, net
2,461 2,527 1,344 1,352 1,069 804 930 903 1,002 893
Other Current Assets
1,217 1,618 1,849 1,153 1,295 1,221 1,215 1,495 1,394 1,151
Plant, Property, & Equipment, net
3,181 3,310 3,299 3,416 3,412 3,247 3,601 3,182 2,502 2,188
Total Noncurrent Assets
17,411 16,676 11,464 12,604 14,320 15,605 14,047 12,597 11,643 10,617
Goodwill
6,479 6,219 5,749 5,761 5,762 5,758 5,706 4,633 3,669 2,664
Intangible Assets
9,691 8,363 1,850 2,221 3,084 3,527 3,120 3,880 3,808 4,085
Noncurrent Deferred & Refundable Income Taxes
324 929 1,226 1,415 1,370 3,232 2,154 596 - -
Other Noncurrent Operating Assets
917 1,165 1,933 2,315 3,332 1,680 1,691 432 1,336 1,108
Total Liabilities & Shareholders' Equity
28,049 26,845 24,554 23,877 24,619 27,234 25,289 23,653 22,877 19,505
Total Liabilities
11,333 12,045 11,166 12,918 13,933 13,895 12,257 11,055 10,748 10,130
Total Current Liabilities
5,529 3,434 3,273 4,298 3,742 4,864 3,295 3,368 3,420 2,578
Short-Term Debt
1,749 150 0.00 999 0.00 1,496 0.00 3.20 4.70 4.80
Accounts Payable
424 403 492 589 455 531 371 396 280 267
Current Deferred & Payable Income Tax Liabilities
548 257 260 175 142 71 64 68 232 209
Other Current Liabilities
2,808 2,624 2,521 2,535 3,145 2,766 2,861 2,901 2,904 2,097
Total Noncurrent Liabilities
5,805 8,611 7,893 8,619 10,191 9,031 8,962 7,686 7,328 7,552
Long-Term Debt
4,547 6,788 6,281 6,274 7,426 4,459 5,937 5,935 6,513 6,522
Noncurrent Deferred & Payable Income Tax Liabilities
191 642 335 695 1,033 2,811 1,636 123 93 125
Other Noncurrent Operating Liabilities
1,067 1,181 1,277 1,651 1,732 1,762 1,389 1,629 723 906
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
16,716 14,799 13,388 10,960 10,686 13,339 13,032 12,598 12,129 9,375
Total Preferred & Common Equity
16,716 14,799 13,398 10,896 10,700 13,343 13,040 12,613 12,140 9,373
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
16,716 14,799 13,398 10,896 10,700 13,343 13,040 12,613 12,140 9,373
Common Stock
570 303 73 68 0.10 0.10 0.10 98 0.10 0.10
Retained Earnings
19,260 17,628 16,467 13,912 13,976 16,455 16,257 15,810 15,072 12,208
Treasury Stock
-2,977 -2,977 -2,977 -2,977 -2,977 -2,977 -2,977 -2,977 -2,612 -2,612
Accumulated Other Comprehensive Income / (Loss)
-136 -154 -165 -107 -299 -135 -240 -318 -320 -224

Quarterly Balance Sheets for Biogen

This table presents Biogen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Total Assets
28,033 28,049 28,313 26,804 26,568 26,845 28,193 25,157 24,598 24,554 24,854
Total Current Assets
7,626 7,457 6,831 7,109 6,756 6,859 8,454 10,432 9,763 9,791 9,766
Cash & Equivalents
2,598 2,375 1,699 1,909 1,074 1,050 2,288 2,618 2,898 3,419 3,676
Accounts Receivable
1,997 1,405 1,988 2,078 2,000 1,664 2,210 2,124 1,634 1,705 1,569
Inventories, net
2,274 2,461 2,469 2,506 2,517 2,527 2,982 1,334 1,281 1,344 1,375
Other Current Assets
757 1,217 674 615 1,165 1,618 974 896 1,806 1,849 1,911
Plant, Property, & Equipment, net
3,132 3,181 3,211 3,249 3,275 3,310 3,302 3,307 3,301 3,299 3,266
Total Noncurrent Assets
17,275 17,411 18,272 16,446 16,536 16,676 16,438 11,418 11,535 11,464 11,822
Goodwill
6,477 6,479 6,486 6,227 6,227 6,219 6,808 5,754 5,752 5,749 5,741
Intangible Assets
9,585 9,691 9,806 8,233 8,285 8,363 7,345 1,776 1,813 1,850 2,009
Noncurrent Deferred & Refundable Income Taxes
308 324 969 915 898 929 1,070 1,208 1,212 1,226 1,175
Other Noncurrent Operating Assets
906 917 1,012 1,071 1,126 1,165 1,216 1,471 1,780 1,933 2,037
Total Liabilities & Shareholders' Equity
28,033 28,049 28,313 26,804 26,568 26,845 28,193 25,157 24,598 24,554 24,854
Total Liabilities
11,054 11,333 11,954 10,915 11,355 12,045 13,714 10,696 10,811 11,166 12,087
Total Current Liabilities
5,297 5,529 5,425 3,108 3,223 3,434 5,022 3,187 3,015 3,273 3,926
Short-Term Debt
1,749 1,749 1,748 0.00 250 150 500 - - 0.00 0.00
Accounts Payable
392 424 423 355 387 403 440 445 491 492 383
Current Deferred & Payable Income Tax Liabilities
626 548 499 282 231 257 244 260 236 260 237
Other Current Liabilities
2,531 2,808 2,755 2,472 2,355 2,624 3,838 2,481 2,288 2,521 3,306
Total Noncurrent Liabilities
5,757 5,805 6,529 7,807 8,132 8,611 8,691 7,510 7,797 7,893 8,161
Long-Term Debt
4,549 4,547 4,546 6,292 6,290 6,788 6,786 6,285 6,283 6,281 6,279
Noncurrent Deferred & Payable Income Tax Liabilities
133 191 882 591 658 642 728 144 251 335 329
Other Noncurrent Operating Liabilities
1,075 1,067 1,101 924 1,184 1,181 1,177 1,081 1,263 1,277 1,553
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
16,979 16,716 16,359 15,889 15,213 14,799 14,480 14,461 13,787 13,388 12,767
Total Preferred & Common Equity
16,979 16,716 16,359 15,889 15,213 14,799 14,484 14,467 13,797 13,398 12,776
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
16,979 16,716 16,359 15,889 15,213 14,799 14,484 14,467 13,797 13,398 12,776
Common Stock
630 570 489 408 330 303 242 171 91 73 0.10
Retained Earnings
19,500 19,260 18,993 18,605 18,021 17,628 17,378 17,446 16,854 16,467 15,916
Treasury Stock
-2,977 -2,977 -2,977 -2,977 -2,977 -2,977 -2,977 -2,977 -2,977 -2,977 -2,977
Accumulated Other Comprehensive Income / (Loss)
-175 -136 -146 -146 -161 -154 -159 -173 -172 -165 -164

Annual Metrics And Ratios for Biogen

This table displays calculated financial ratios and metrics derived from Biogen's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics
- - - - - - - - - -
Revenue Growth
-1.62% -3.32% -7.36% -18.32% -6.49% 6.88% 9.61% 7.21% 6.36% 10.93%
EBITDA Growth
54.09% -55.64% 84.07% -59.44% -27.48% 15.89% 5.48% 10.58% 4.62% 15.82%
EBIT Growth
46.98% -63.90% 105.81% -65.42% -29.17% 20.79% 15.03% 3.97% 3.48% 20.80%
NOPAT Growth
33.40% -49.68% 69.54% -53.70% -38.02% 32.08% 60.46% -27.89% 4.33% 24.30%
Net Income Growth
40.53% -60.78% 71.43% -57.45% -31.04% 31.62% 67.56% -27.75% 2.85% 22.15%
EPS Growth
40.28% -61.81% 100.67% -58.06% -21.07% 45.60% 81.04% -29.59% 10.37% 24.01%
Operating Cash Flow Growth
85.85% 11.77% -61.97% -13.95% -40.25% 14.40% 35.96% -0.79% 17.04% 33.22%
Free Cash Flow Firm Growth
138.23% -321.32% -18.97% 23.51% -64.30% 197.19% 14.98% -27.76% 28.14% -8.61%
Invested Capital Growth
-0.25% 47.02% 3.93% -8.09% 9.85% -4.58% 19.20% 7.95% 12.45% 20.18%
Revenue Q/Q Growth
0.71% -1.58% -1.83% -1.07% -5.74% 1.02% 1.66% 3.67% 0.29% 1.88%
EBITDA Q/Q Growth
-8.42% -7.71% 20.20% 12.82% -17.44% 3.37% -3.40% 10.56% -3.88% -1.22%
EBIT Q/Q Growth
-14.21% -13.59% 24.45% 15.09% -21.42% 4.61% 0.25% 12.30% -4.78% -1.35%
NOPAT Q/Q Growth
2.38% 5.89% 42.29% -8.72% -31.77% 9.69% 32.19% -23.47% -5.05% 0.04%
Net Income Q/Q Growth
1.10% -20.56% 23.84% -17.96% -21.04% 9.17% 33.04% -23.37% -4.66% -1.48%
EPS Q/Q Growth
1.09% -20.30% 6.26% -1.61% -17.77% 11.81% 39.50% -26.96% -4.35% 0.33%
Operating Cash Flow Q/Q Growth
35.18% 13.79% -42.26% 49.51% -35.49% 0.92% 6.49% -1.38% 7.96% 8.61%
Free Cash Flow Firm Q/Q Growth
386.89% -6.88% -21.35% 139.39% -57.32% 14.76% 2.38% -8.09% 23.85% -4.75%
Invested Capital Q/Q Growth
-1.51% 6.21% 6.00% -4.86% 8.47% -2.07% 0.26% -7.82% -2.80% 4.30%
Profitability Metrics
- - - - - - - - - -
Gross Margin
76.12% 74.24% 77.61% 80.79% 86.57% 86.40% 86.50% 86.72% 87.08% 88.48%
EBITDA Margin
29.03% 18.54% 40.40% 20.33% 40.94% 52.79% 48.69% 50.59% 49.05% 49.87%
Operating Margin
23.25% 16.39% 34.24% 15.89% 33.84% 48.98% 43.77% 43.55% 45.00% 45.44%
EBIT Margin
19.70% 13.18% 35.31% 15.89% 37.54% 49.56% 43.85% 41.79% 43.09% 44.29%
Profit (Net Income) Margin
16.87% 11.81% 29.11% 15.73% 30.20% 40.96% 33.26% 21.75% 32.28% 33.38%
Tax Burden Percent
85.63% 89.57% 82.45% 98.99% 80.45% 82.64% 75.84% 52.06% 74.92% 75.37%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
14.37% 10.43% 17.62% 3.01% 19.66% 16.25% 24.16% 47.94% 25.08% 24.37%
Return on Invested Capital (ROIC)
9.32% 8.31% 20.79% 11.98% 25.98% 42.95% 34.56% 24.51% 37.41% 41.58%
ROIC Less NNEP Spread (ROIC-NNEP)
3.32% -0.29% 26.42% 13.03% 45.66% 41.19% 42.34% 35.72% 75.09% 50.44%
Return on Net Nonoperating Assets (RNNOA)
1.03% -0.07% 3.54% 3.99% 7.82% 1.71% 0.35% -2.91% -3.04% -5.98%
Return on Equity (ROE)
10.36% 8.24% 24.33% 15.96% 33.80% 44.66% 34.91% 21.60% 34.37% 35.60%
Cash Return on Invested Capital (CROIC)
9.57% -29.76% 16.93% 20.41% 16.60% 47.64% 17.04% 16.86% 25.69% 23.25%
Operating Return on Assets (OROA)
6.94% 5.05% 14.83% 7.20% 19.47% 27.13% 24.11% 22.05% 23.28% 28.19%
Return on Assets (ROA)
5.95% 4.52% 12.23% 7.12% 15.66% 22.42% 18.28% 11.48% 17.44% 21.25%
Return on Common Equity (ROCE)
10.36% 8.24% 24.27% 15.93% 33.83% 44.68% 34.94% 21.62% 34.39% 35.58%
Return on Equity Simple (ROE_SIMPLE)
9.76% 7.85% 22.11% 15.86% 37.95% 44.13% 34.31% 21.17% 30.44% 38.34%
Net Operating Profit after Tax (NOPAT)
1,926 1,444 2,870 1,693 3,656 5,898 4,466 2,783 3,860 3,699
NOPAT Margin
19.91% 14.68% 28.21% 15.41% 27.19% 41.02% 33.19% 22.67% 33.71% 34.37%
Net Nonoperating Expense Percent (NNEP)
6.00% 8.60% -5.63% -1.05% -19.68% 1.76% -7.78% -11.21% -37.68% -8.86%
Return On Investment Capital (ROIC_SIMPLE)
8.37% 6.64% 14.59% 9.28% 20.18% 30.57% 23.54% 15.01% 20.70% 23.26%
Cost of Revenue to Revenue
23.88% 25.76% 22.39% 19.21% 13.43% 13.60% 13.50% 13.28% 12.92% 11.52%
SG&A Expenses to Revenue
24.84% 25.92% 23.63% 24.35% 18.63% 16.52% 15.66% 15.76% 17.00% 19.63%
R&D to Revenue
21.10% 25.03% 21.93% 22.94% 30.24% 15.86% 20.14% 19.34% 17.24% 18.70%
Operating Expenses to Revenue
52.87% 57.85% 43.36% 64.90% 52.73% 37.42% 42.73% 43.17% 42.09% 43.04%
Earnings before Interest and Taxes (EBIT)
1,906 1,297 3,592 1,745 5,048 7,126 5,900 5,129 4,933 4,767
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,809 1,823 4,110 2,233 5,505 7,591 6,550 6,210 5,616 5,368
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.33 2.53 2.98 3.23 3.52 4.01 4.65 5.34 5.08 7.29
Price to Tangible Book Value (P/TBV)
40.82 172.63 6.88 12.10 20.32 13.19 14.39 16.43 13.23 26.02
Price to Revenue (P/Rev)
2.30 3.81 3.92 3.21 2.80 3.72 4.51 5.49 5.39 6.34
Price to Earnings (P/E)
13.65 32.29 13.09 22.65 9.42 9.09 13.68 26.53 16.66 19.25
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
7.32% 3.10% 7.64% 4.42% 10.62% 11.00% 7.31% 3.77% 6.00% 5.19%
Enterprise Value to Invested Capital (EV/IC)
1.27 2.10 2.88 2.80 2.83 4.00 4.39 5.64 5.54 7.07
Enterprise Value to Revenue (EV/Rev)
2.71 4.41 3.99 3.45 3.10 3.73 4.58 5.42 5.28 6.38
Enterprise Value to EBITDA (EV/EBITDA)
9.33 23.80 9.87 16.97 7.58 7.06 9.41 10.72 10.77 12.79
Enterprise Value to EBIT (EV/EBIT)
13.75 33.45 11.29 21.71 8.26 7.52 10.45 12.98 12.26 14.40
Enterprise Value to NOPAT (EV/NOPAT)
13.60 30.04 14.13 22.38 11.41 9.09 13.80 23.91 15.67 18.55
Enterprise Value to Operating Cash Flow (EV/OCF)
9.11 28.04 29.29 10.41 9.86 7.57 9.96 14.62 13.18 17.51
Enterprise Value to Free Cash Flow (EV/FCFF)
13.25 0.00 17.35 13.13 17.86 8.19 28.00 34.76 22.82 33.18
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.38 0.47 0.47 0.66 0.69 0.45 0.46 0.47 0.54 0.70
Long-Term Debt to Equity
0.27 0.46 0.47 0.57 0.69 0.33 0.46 0.47 0.54 0.70
Financial Leverage
0.31 0.23 0.13 0.31 0.17 0.04 0.01 -0.08 -0.04 -0.12
Leverage Ratio
1.74 1.82 1.99 2.24 2.16 1.99 1.91 1.88 1.97 1.68
Compound Leverage Factor
1.74 1.82 1.99 2.24 2.16 1.99 1.91 1.88 1.97 1.68
Debt to Total Capital
27.36% 31.92% 31.93% 39.89% 41.00% 30.86% 31.30% 32.04% 34.95% 41.04%
Short-Term Debt to Total Capital
7.60% 0.69% 0.00% 5.48% 0.00% 7.75% 0.00% 0.02% 0.03% 0.03%
Long-Term Debt to Total Capital
19.76% 31.23% 31.93% 34.41% 41.00% 23.11% 31.30% 32.02% 34.93% 41.01%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% -0.05% 0.35% -0.08% -0.02% -0.04% -0.08% -0.06% 0.01%
Common Equity to Total Capital
72.64% 68.08% 68.12% 59.76% 59.08% 69.16% 68.74% 68.04% 65.11% 58.94%
Debt to EBITDA
2.24 3.81 1.53 3.26 1.35 0.78 0.91 0.96 1.16 1.22
Net Debt to EBITDA
1.40 3.23 0.17 1.15 0.73 0.01 0.16 -0.13 -0.22 0.06
Long-Term Debt to EBITDA
1.62 3.72 1.53 2.81 1.35 0.59 0.91 0.96 1.16 1.22
Debt to NOPAT
3.27 4.80 2.19 4.30 2.03 1.01 1.33 2.13 1.69 1.76
Net Debt to NOPAT
2.04 4.08 0.24 1.52 1.11 0.01 0.23 -0.29 -0.31 0.09
Long-Term Debt to NOPAT
2.36 4.70 2.19 3.71 2.03 0.76 1.33 2.13 1.69 1.76
Altman Z-Score
2.79 3.47 4.30 3.33 3.79 4.70 5.38 6.06 5.86 6.53
Noncontrolling Interest Sharing Ratio
0.00% -0.03% 0.22% 0.23% -0.08% -0.05% -0.09% -0.11% -0.04% 0.04%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.35 2.00 2.99 1.83 1.84 1.72 2.32 2.34 2.55 2.60
Quick Ratio
0.68 0.79 2.02 1.25 1.21 1.31 1.67 1.63 1.85 1.81
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
1,977 -5,173 2,337 2,885 2,335 6,542 2,201 1,915 2,650 2,068
Operating Cash Flow to CapEx
4,417.05% 558.56% 576.07% 1,582.57% 995.72% 0.00% 272.51% 220.13% 252.59% 262.52%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.35 0.38 0.42 0.45 0.52 0.55 0.55 0.53 0.54 0.64
Accounts Receivable Turnover
6.31 5.84 6.25 6.34 7.09 7.49 7.18 7.60 8.58 8.54
Inventory Turnover
0.93 1.31 1.69 1.74 1.93 2.26 1.98 1.71 1.56 1.46
Fixed Asset Turnover
2.98 2.98 3.03 3.22 4.04 4.20 3.97 4.32 4.88 5.45
Accounts Payable Turnover
5.58 5.66 4.22 4.04 3.66 4.34 4.74 4.83 5.40 5.00
Days Sales Outstanding (DSO)
57.88 62.51 58.38 57.55 51.50 48.73 50.81 48.01 42.54 42.72
Days Inventory Outstanding (DIO)
394.00 278.92 215.95 209.35 189.33 161.85 184.14 213.21 233.88 249.74
Days Payable Outstanding (DPO)
65.36 64.46 86.57 90.32 99.65 84.12 76.97 75.61 67.54 73.06
Cash Conversion Cycle (CCC)
386.52 276.97 187.76 176.58 141.19 126.46 157.98 185.61 208.88 219.39
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
20,637 20,688 14,071 13,538 14,730 13,410 14,054 11,790 10,922 9,712
Invested Capital Turnover
0.47 0.57 0.74 0.78 0.96 1.05 1.04 1.08 1.11 1.21
Increase / (Decrease) in Invested Capital
-51 6,617 533 -1,192 1,320 -644 2,264 869 1,209 1,631
Enterprise Value (EV)
26,204 43,384 40,550 37,885 41,709 53,609 61,645 66,547 60,481 68,626
Market Capitalization
22,283 37,495 39,877 35,242 37,679 53,543 60,630 67,370 61,700 68,286
Book Value per Share
$114.71 $102.14 $93.04 $74.18 $69.54 $73.95 $64.72 $59.64 $55.80 $42.05
Tangible Book Value per Share
$3.75 $1.50 $40.27 $19.84 $12.05 $22.49 $20.91 $19.39 $21.43 $11.77
Total Capital
23,012 21,738 19,669 18,233 18,112 19,294 18,968 18,536 18,646 15,901
Total Debt
6,296 6,938 6,281 7,273 7,426 5,955 5,937 5,938 6,517 6,526
Total Long-Term Debt
4,547 6,788 6,281 6,274 7,426 4,459 5,937 5,935 6,513 6,522
Net Debt
3,921 5,888 683 2,579 4,044 71 1,023 -808 -1,207 337
Capital Expenditures (CapEx)
65 277 240 230 425 -109 2,271 2,067 1,816 1,493
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,302 2,525 1,626 755 535 538 808 819 422 699
Debt-free Net Working Capital (DFNWC)
3,677 3,575 6,518 4,557 3,145 5,014 4,346 4,508 5,317 4,127
Net Working Capital (NWC)
1,928 3,425 6,518 3,558 3,145 3,518 4,346 4,505 5,312 4,123
Net Nonoperating Expense (NNE)
294 283 -92 -35 -405 9.64 -8.34 113 164 106
Net Nonoperating Obligations (NNO)
3,921 5,888 683 2,579 4,044 71 1,023 -808 -1,207 337
Total Depreciation and Amortization (D&A)
903 526 518 488 457 465 651 1,081 683 600
Debt-free, Cash-free Net Working Capital to Revenue
13.45% 25.67% 15.98% 6.87% 3.98% 3.74% 6.00% 6.68% 3.69% 6.49%
Debt-free Net Working Capital to Revenue
38.00% 36.35% 64.07% 41.50% 23.39% 34.87% 32.30% 36.73% 46.44% 38.35%
Net Working Capital to Revenue
19.93% 34.82% 64.07% 32.40% 23.39% 24.47% 32.30% 36.70% 46.40% 38.30%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$11.21 $8.02 $20.96 $10.44 $24.86 $31.47 $21.63 $11.94 $15.61 $14.16
Adjusted Weighted Average Basic Shares Outstanding
145.60M 144.70M 145.30M 149.10M 160.90M 187.10M 204.90M 212.60M 237.26M 250.63M
Adjusted Diluted Earnings per Share
$11.18 $7.97 $20.87 $10.40 $24.80 $31.42 $21.58 $11.92 $15.58 $14.12
Adjusted Weighted Average Diluted Shares Outstanding
145.90M 145.60M 146M 149.60M 161.30M 187.40M 205.30M 213M 237.70M 251.17M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $31.47 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
146.37M 145.36M 144.49M 146.96M 152.34M 174.06M 196.71M 211.56M 234.60M 237.56M
Normalized Net Operating Profit after Tax (NOPAT)
1,900 1,640 2,391 1,644 3,512 5,892 4,465 2,816 4,236 3,793
Normalized NOPAT Margin
19.64% 16.67% 23.50% 14.97% 26.12% 40.98% 33.19% 22.94% 37.00% 35.24%
Pre Tax Income Margin
19.70% 13.18% 35.31% 15.89% 37.54% 49.56% 43.85% 41.79% 43.09% 44.29%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% -1.06% -0.42% 5.46% 1.75% -0.07% 0.81% 16.36% 0.00% 1.56%
Augmented Payout Ratio
0.00% -1.06% 24.91% 109.66% 166.24% 99.58% 98.10% 67.50% 27.06% 140.71%

Quarterly Metrics And Ratios for Biogen

This table displays calculated financial ratios and metrics derived from Biogen's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
6.13% 2.87% -2.55% 0.36% -7.00% -6.20% 0.87% -5.14% -2.72% -6.94% -9.73%
EBITDA Growth
-16.85% 10.95% 4,326.54% 14.80% 19.22% 26.54% -101.09% -41.22% 12.25% 1,776.22% 251.59%
EBIT Growth
-33.05% 4.61% 419.41% -1.33% 6.05% 22.50% -110.30% -44.22% 26.17% 586.36% 371.01%
NOPAT Growth
-38.87% 12.13% 493.06% -1.63% 1.50% 14.89% -108.71% -43.65% 74.75% 4,580.45% 258.01%
Net Income Growth
-38.87% 7.15% 668.81% -1.63% 1.50% -54.70% -106.02% -43.96% 77.39% 2,767.48% 256.77%
EPS Growth
-39.26% 7.06% 665.96% -1.72% 1.12% -54.42% -105.99% -43.78% 29.61% 49.20% 253.15%
Operating Cash Flow Growth
-53.13% 5,987.20% 57.93% 28.50% 21.50% 107.14% -10.38% -33.88% 181.40% -120.88% -17.92%
Free Cash Flow Firm Growth
103.87% 110.36% 82.75% 51.58% -1,374.72% -7,376.57% -401.59% -182.63% -127.22% -106.79% 728.48%
Invested Capital Growth
0.00% -0.25% 7.58% 50.62% 47.18% 47.02% 46.73% 0.00% 6.12% 3.93% -6.71%
Revenue Q/Q Growth
-0.97% -0.45% 0.04% 7.61% -4.01% -5.69% 3.03% -0.28% -3.18% 1.42% -3.11%
EBITDA Q/Q Growth
-36.83% 26.19% -27.75% 44.38% -15.71% 4,906.79% -101.96% 49.93% -10.53% -58.75% 6.23%
EBIT Q/Q Growth
-51.00% 40.82% -35.45% 50.32% -23.44% 529.96% -119.94% 61.56% -11.56% -63.85% 8.00%
NOPAT Q/Q Growth
-58.61% 49.57% -33.43% 48.35% -24.08% 624.28% -116.66% 53.07% -14.06% -60.26% 7.80%
Net Income Q/Q Growth
-9.82% -31.35% -33.43% 48.35% 58.06% 464.42% -111.51% 53.07% -29.46% -51.58% 7.20%
EPS Q/Q Growth
-9.89% -31.58% -33.50% 48.15% 58.82% 461.70% -111.55% 52.43% -28.42% -52.42% 8.29%
Operating Cash Flow Q/Q Growth
-65.92% -18.67% 49.50% 13.12% 4,325.60% -97.89% 21.64% 6.96% 360.17% -126.48% -10.25%
Free Cash Flow Firm Q/Q Growth
-61.87% 158.14% 82.55% 0.09% -2.24% 3.23% 51.01% -2,942.93% -418.33% -103.90% -86.58%
Invested Capital Q/Q Growth
0.20% -1.51% 3.36% -1.97% -0.04% 6.21% 44.72% -4.21% -0.15% 6.00% 0.00%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
74.11% 76.23% 74.10% 77.85% 76.33% 74.09% 73.93% 75.87% 73.09% 77.56% 81.28%
EBITDA Margin
22.45% 35.20% 27.77% 38.45% 28.66% 32.63% -0.64% 33.61% 22.35% 24.19% 59.47%
Operating Margin
12.80% 25.87% 18.29% 28.35% 20.29% 25.44% -5.58% 28.83% 17.80% 19.48% 54.66%
EBIT Margin
12.80% 25.87% 18.29% 28.35% 20.29% 25.44% -5.58% 28.83% 17.80% 19.48% 54.66%
Profit (Net Income) Margin
9.89% 10.86% 15.76% 23.68% 17.18% 10.43% -2.70% 24.16% 15.74% 21.60% 45.24%
Tax Burden Percent
77.28% 91.49% 86.14% 83.53% 84.64% 85.36% 48.37% 83.79% 88.43% 91.01% 82.77%
Interest Burden Percent
100.00% 45.90% 100.00% 100.00% 100.00% 48.03% 100.00% 100.00% 100.00% 121.83% 100.00%
Effective Tax Rate
22.72% 8.51% 13.86% 16.47% 15.36% 14.64% 0.00% 16.21% 11.57% 8.99% 17.23%
Return on Invested Capital (ROIC)
4.70% 11.09% 7.49% 13.58% 9.56% 12.29% -2.38% 35.80% 11.65% 13.07% 34.09%
ROIC Less NNEP Spread (ROIC-NNEP)
4.70% 4.68% 7.49% 13.58% 9.56% 4.09% -1.27% 35.80% 11.65% 19.10% 34.09%
Return on Net Nonoperating Assets (RNNOA)
1.34% 1.46% 2.33% 1.51% 1.89% 0.95% -0.26% -2.48% 0.74% 2.56% 5.56%
Return on Equity (ROE)
6.03% 12.54% 9.82% 15.09% 11.45% 13.24% -2.64% 33.32% 12.40% 15.62% 39.65%
Cash Return on Invested Capital (CROIC)
8.56% 9.57% 2.01% -31.89% -29.85% -29.76% -29.55% -161.77% 16.29% 16.93% 21.61%
Operating Return on Assets (OROA)
4.60% 9.12% 6.22% 10.55% 7.66% 9.74% -2.10% 11.43% 7.24% 8.18% 23.28%
Return on Assets (ROA)
3.56% 3.83% 5.36% 8.81% 6.49% 3.99% -1.02% 9.58% 6.40% 9.07% 19.27%
Return on Common Equity (ROCE)
6.03% 12.54% 9.82% 15.09% 11.45% 13.25% -2.64% 33.33% 12.41% 15.59% 38.91%
Return on Equity Simple (ROE_SIMPLE)
8.71% 0.00% 9.87% 7.29% 7.67% 0.00% 10.09% 18.42% 22.69% 0.00% 18.72%
Net Operating Profit after Tax (NOPAT)
241 581 389 584 393 518 -99 593 388 451 1,135
NOPAT Margin
9.89% 23.67% 15.76% 23.68% 17.18% 21.72% -3.91% 24.16% 15.74% 17.73% 45.24%
Net Nonoperating Expense Percent (NNEP)
0.00% 6.41% 0.00% 0.00% 0.00% 8.20% -1.11% 0.00% 0.00% -6.04% 0.00%
Return On Investment Capital (ROIC_SIMPLE)
1.03% 2.53% 1.72% 2.63% 1.81% 2.38% -0.45% 2.86% 1.93% 2.29% 5.96%
Cost of Revenue to Revenue
25.89% 23.77% 25.90% 22.15% 23.67% 25.91% 26.07% 24.13% 26.91% 22.44% 18.72%
SG&A Expenses to Revenue
23.55% 27.70% 23.86% 22.47% 25.39% 25.50% 31.15% 22.31% 24.56% 24.87% 22.46%
R&D to Revenue
26.11% 21.68% 22.01% 20.85% 19.77% 23.92% 29.10% 23.79% 23.17% 23.65% 21.89%
Operating Expenses to Revenue
61.31% 50.36% 55.81% 49.50% 56.04% 48.65% 79.51% 47.04% 55.29% 58.08% 26.63%
Earnings before Interest and Taxes (EBIT)
311 635 451 699 465 607 -141 708 438 496 1,371
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
546 864 685 948 656 779 -16 826 551 615 1,492
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.18 1.33 1.73 2.12 2.05 2.53 2.57 2.85 2.91 2.98 3.03
Price to Tangible Book Value (P/TBV)
21.84 40.82 417.68 23.62 44.58 172.63 112.21 5.94 6.45 6.88 7.71
Price to Revenue (P/Rev)
2.04 2.30 2.94 3.49 3.23 3.81 3.72 4.13 3.98 3.92 3.74
Price to Earnings (P/E)
13.54 13.65 17.48 29.13 26.78 32.29 25.46 15.47 12.83 13.09 13.53
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
7.39% 7.32% 5.72% 3.43% 3.73% 3.10% 3.93% 6.46% 7.79% 7.64% 7.39%
Enterprise Value to Invested Capital (EV/IC)
1.15 1.27 1.57 1.88 1.78 2.10 2.17 2.99 2.88 2.88 2.96
Enterprise Value to Revenue (EV/Rev)
2.42 2.71 3.42 3.94 3.80 4.41 4.22 4.03 4.00 3.99 3.79
Enterprise Value to EBITDA (EV/EBITDA)
7.80 9.33 10.70 16.11 16.36 23.80 21.37 11.55 9.95 9.87 11.48
Enterprise Value to EBIT (EV/EBIT)
11.32 13.75 14.78 23.40 22.40 33.45 28.13 13.35 11.31 11.29 13.60
Enterprise Value to NOPAT (EV/NOPAT)
13.41 13.60 17.45 26.56 25.39 30.04 30.95 15.63 13.33 14.13 19.46
Enterprise Value to Operating Cash Flow (EV/OCF)
9.19 9.11 15.43 21.38 22.31 28.04 31.05 28.16 24.09 29.29 16.37
Enterprise Value to Free Cash Flow (EV/FCFF)
13.41 13.25 80.84 0.00 0.00 0.00 0.00 0.00 18.19 17.35 13.21
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.37 0.38 0.38 0.40 0.43 0.47 0.50 0.43 0.46 0.47 0.49
Long-Term Debt to Equity
0.27 0.27 0.28 0.40 0.41 0.46 0.47 0.43 0.46 0.47 0.49
Financial Leverage
0.28 0.31 0.31 0.11 0.20 0.23 0.20 -0.07 0.06 0.13 0.16
Leverage Ratio
1.70 1.74 1.83 1.71 1.76 1.82 1.95 1.74 1.94 1.99 2.06
Compound Leverage Factor
1.70 0.80 1.83 1.71 1.76 0.88 1.95 1.74 1.94 2.42 2.06
Debt to Total Capital
27.06% 27.36% 27.78% 28.37% 30.07% 31.92% 33.48% 30.29% 31.30% 31.93% 32.97%
Short-Term Debt to Total Capital
7.51% 7.60% 7.72% 0.00% 1.15% 0.69% 2.30% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
19.54% 19.76% 20.07% 28.37% 28.92% 31.23% 31.18% 30.29% 31.30% 31.93% 32.97%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.02% -0.03% -0.05% -0.05% -0.05%
Common Equity to Total Capital
72.94% 72.64% 72.22% 71.63% 69.93% 68.08% 66.54% 69.74% 68.74% 68.12% 67.08%
Debt to EBITDA
2.07 2.24 2.05 2.66 2.91 3.81 3.69 1.80 1.55 1.53 1.84
Net Debt to EBITDA
1.22 1.40 1.50 1.85 2.44 3.23 2.53 -0.29 0.06 0.17 0.15
Long-Term Debt to EBITDA
1.50 1.62 1.48 2.66 2.80 3.72 3.44 1.80 1.55 1.53 1.84
Debt to NOPAT
3.56 3.27 3.34 4.38 4.52 4.80 5.34 2.44 2.07 2.19 3.11
Net Debt to NOPAT
2.09 2.04 2.44 3.05 3.78 4.08 3.67 -0.39 0.09 0.24 0.25
Long-Term Debt to NOPAT
2.57 2.36 2.42 4.38 4.35 4.70 4.98 2.44 2.07 2.19 3.11
Altman Z-Score
2.55 2.64 2.81 3.45 3.18 3.38 2.98 4.12 3.99 3.88 3.70
Noncontrolling Interest Sharing Ratio
0.00% 0.00% -0.01% -0.02% -0.03% -0.03% -0.05% -0.04% -0.07% 0.22% 1.87%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.44 1.35 1.26 2.29 2.10 2.00 1.68 3.27 3.24 2.99 2.49
Quick Ratio
0.87 0.68 0.68 1.28 0.95 0.79 0.90 2.57 2.21 2.02 1.65
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
241 632 -1,087 -6,230 -6,235 -6,099 -6,302 -12,866 -423 -82 2,090
Operating Cash Flow to CapEx
698.92% 1,936.13% 1,893.93% 1,868.06% 1,205.23% 19.17% 798.38% 685.92% 683.63% -202.55% 1,118.44%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.36 0.35 0.34 0.37 0.38 0.38 0.38 0.40 0.41 0.42 0.43
Accounts Receivable Turnover
4.91 6.31 4.58 4.60 5.32 5.84 5.29 4.69 6.31 6.25 6.30
Inventory Turnover
1.00 0.93 0.86 1.23 1.27 1.31 1.14 1.72 1.70 1.69 1.74
Fixed Asset Turnover
3.06 2.98 2.95 2.95 2.94 2.98 3.04 3.02 3.04 3.03 3.10
Accounts Payable Turnover
6.16 5.58 5.44 5.92 5.49 5.66 6.04 5.15 4.72 4.22 5.84
Days Sales Outstanding (DSO)
74.29 57.88 79.74 79.29 68.63 62.51 69.00 77.75 57.83 58.38 57.97
Days Inventory Outstanding (DIO)
364.67 394.00 424.24 296.15 287.26 278.92 319.88 212.00 214.87 215.95 209.90
Days Payable Outstanding (DPO)
59.26 65.36 67.14 61.70 66.43 64.46 60.44 70.81 77.27 86.57 62.52
Cash Conversion Cycle (CCC)
379.71 386.52 436.83 313.75 289.47 276.97 328.45 218.94 195.44 187.76 205.34
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
20,678 20,637 20,954 20,272 20,679 20,688 19,478 13,459 14,050 14,071 13,275
Invested Capital Turnover
0.47 0.47 0.48 0.57 0.56 0.57 0.61 1.48 0.74 0.74 0.75
Increase / (Decrease) in Invested Capital
-0.50 -51 1,476 6,813 6,629 6,617 6,204 13,459 810 533 -955
Enterprise Value (EV)
23,729 26,204 32,830 38,135 36,710 43,384 42,215 40,222 40,425 40,550 39,244
Market Capitalization
20,030 22,283 28,235 33,752 31,244 37,495 37,221 41,230 40,171 39,877 38,745
Book Value per Share
$115.99 $114.71 $112.31 $109.13 $104.77 $102.14 $100.01 $99.95 $95.49 $93.04 $88.04
Tangible Book Value per Share
$6.26 $3.75 $0.46 $9.81 $4.83 $1.50 $2.29 $47.93 $43.13 $40.27 $34.63
Total Capital
23,277 23,012 22,653 22,181 21,753 21,738 21,766 20,745 20,070 19,669 19,046
Total Debt
6,298 6,296 6,294 6,292 6,540 6,938 7,286 6,285 6,283 6,281 6,279
Total Long-Term Debt
4,549 4,547 4,546 6,292 6,290 6,788 6,786 6,285 6,283 6,281 6,279
Net Debt
3,700 3,921 4,595 4,383 5,466 5,888 4,998 -1,002 263 683 508
Capital Expenditures (CapEx)
37 39 49 34 46 65 74 71 67 86 59
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,479 1,302 1,454 2,091 2,709 2,525 1,644 1,167 1,706 1,626 928
Debt-free Net Working Capital (DFNWC)
4,078 3,677 3,154 4,000 3,783 3,575 3,932 7,245 6,748 6,518 5,839
Net Working Capital (NWC)
2,329 1,928 1,406 4,000 3,533 3,425 3,432 7,245 6,748 6,518 5,839
Net Nonoperating Expense (NNE)
0.00 314 0.00 0.00 0.00 269 -31 0.00 0.00 -98 0.00
Net Nonoperating Obligations (NNO)
3,700 3,921 4,595 4,383 5,466 5,888 4,998 -1,002 263 683 508
Total Depreciation and Amortization (D&A)
235 229 234 249 192 172 125 117 112 120 121
Debt-free, Cash-free Net Working Capital to Revenue
15.07% 13.45% 15.14% 21.62% 28.03% 25.67% 16.45% 11.70% 16.89% 15.98% 8.96%
Debt-free Net Working Capital to Revenue
41.54% 38.00% 32.82% 41.36% 39.15% 36.35% 39.34% 72.66% 66.78% 64.07% 56.35%
Net Working Capital to Revenue
23.72% 19.93% 14.63% 41.36% 36.57% 34.82% 34.34% 72.66% 66.78% 64.07% 56.35%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.65 $1.82 $2.67 $4.01 $2.71 $1.71 ($0.47) $4.09 $2.69 $3.79 $7.86
Adjusted Weighted Average Basic Shares Outstanding
146.10M 145.60M 145.70M 145.60M 145.20M 144.70M 144.80M 144.70M 144.40M 145.30M 144.40M
Adjusted Diluted Earnings per Share
$1.64 $1.82 $2.66 $4.00 $2.70 $1.70 ($0.47) $4.07 $2.67 $3.73 $7.84
Adjusted Weighted Average Diluted Shares Outstanding
146.60M 145.90M 146.10M 145.90M 145.90M 145.60M 144.80M 145.50M 145.20M 146M 144.80M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
146.53M 146.37M 145.72M 145.66M 145.60M 145.36M 144.90M 144.82M 144.74M 144.49M 144.00M
Normalized Net Operating Profit after Tax (NOPAT)
275 586 415 515 403 603 -46 622 396 280 729
Normalized NOPAT Margin
11.32% 23.87% 16.82% 20.90% 17.60% 25.25% -1.80% 25.33% 16.08% 10.99% 29.06%
Pre Tax Income Margin
12.80% 11.88% 18.29% 28.35% 20.29% 12.22% -5.58% 28.83% 17.80% 23.73% 54.66%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% -0.50% -0.92% -1.04% -1.06% -0.30% -0.08% -0.40% -0.42% -0.53%
Augmented Payout Ratio
0.00% 0.00% -0.50% -0.92% -1.04% -1.06% -0.30% -0.08% -0.40% 24.91% 30.83%

Frequently Asked Questions About Biogen's Financials

When does Biogen's fiscal year end?

According to the most recent income statement we have on file, Biogen's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Biogen's net income changed over the last 9 years?

Biogen's net income appears to be on a downward trend, with a most recent value of $1.63 billion in 2024, falling from $3.59 billion in 2015. The previous period was $1.16 billion in 2023. Find out what analysts predict for Biogen in the coming months.

What is Biogen's operating income?
Biogen's total operating income in 2024 was $2.25 billion, based on the following breakdown:
  • Total Gross Profit: $7.37 billion
  • Total Operating Expenses: $5.12 billion
How has Biogen revenue changed over the last 9 years?

Over the last 9 years, Biogen's total revenue changed from $10.76 billion in 2015 to $9.68 billion in 2024, a change of -10.1%.

How much debt does Biogen have?

Biogen's total liabilities were at $11.33 billion at the end of 2024, a 5.9% decrease from 2023, and a 11.9% increase since 2015.

How much cash does Biogen have?

In the past 9 years, Biogen's cash and equivalents has ranged from $1.05 billion in 2023 to $3.42 billion in 2022, and is currently $2.38 billion as of their latest financial filing in 2024.

How has Biogen's book value per share changed over the last 9 years?

Over the last 9 years, Biogen's book value per share changed from 42.05 in 2015 to 114.71 in 2024, a change of 172.8%.



This page (NASDAQ:BIIB) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners